The difference between Alnylam and Benitec is the $1b Alnylam has in cash. Also, they have a more advanced pipeline, but in areas that take a long time to evaluate. HBV/HCV are all diseases that can get through clinical trial very quickly. HIV maybe longer, but theoretically, Calimmune may already know if CAL-1 is working.
Alnylam and Benitec hold the lions share of core patents for RNAi. They both have crosslicenced their technologies as well.
cashed up, ready to make medical history, page-23
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)